Pharmaceutical formulations for oral use in hormone replacement therapy comprising ultra-micronized progesterone are disclosed, wherein the ultra-micronized progesterone is combined with a suitable excipient. The preferred excipients comprise medium chain fatty acid-glycol esters and a nonionic surfactant comprising a polyethylene glycol fatty acid ester. In some embodiments C8 to C18 fatty acid esters of glycerol and polyethylene glycol are the preferred nonionic surfactants.L'invention concerne des traitements de substitution hormonale comprenant de la progestérone solubilisée seule et éventuellement associée à un oestrogène, un dosage cyclique/séquentiel combiné-continu, et administrés via des systèmes d'administration HRT transdermique.
